Navigation Links
CLAAD Warns of Increase in Prescription Drug Overdoses

WASHINGTON, Nov. 12, 2012 /PRNewswire-USNewswire/ -- Today, a national organization dedicated to reducing prescription drug abuse urged communities to take extra precautions to prevent medication overdoses.  The not-for-profit Center for Lawful Access and Abuse Deterrence (CLAAD) warned that pain pills without added safety features are expected to flood back into communities in the coming weeks unless the Food and Drug Administration (FDA) takes preventive action. 

In recent years, the makers of the powerful opioid pain relievers OxyContin and Opana removed their traditional products from the market in favor of new versions designed to impede certain forms of intentional abuse.  Preliminary, peer-reviewed evidence indicates that dealers and abusers have less interest in the new drugs with abuse-deterrent features.[1]  The new medications cost no more to consumers than their prior formulations. 

"Pharmaceutical companies have an obligation to make their products safer," said Michael Barnes, spokesman for CLAAD. 

Several drug companies have asked the FDA to approve generic versions of these medications that do not have abuse-deterrent properties.  The FDA could allow the old formulations of the drugs to return to market as early as January 2013. 

"Parents, health care providers, and law enforcement must be prepared to confront the resurgence of more readily abused pain medications, and the overdoses that could follow," Barnes said. 

Earlier this month, CLAAD and nine other public health and safety organizations sent a letter to the FDA urging it to take swift action to foster the widespread adoption of abuse-deterrent medications and to prevent the marketing of generic versions of the drugs that do not have similar safety features. 

A bill before the U.S. House of Representatives, H.R. 6160, would require all manufacturers of opioid pain relievers to utilize abuse-deterrent technologies.  However, the measure is not likely to pass before January.

About the Center for Lawful Access and Abuse Deterrence
The not-for-profit Center for Lawful Access and Abuse Deterrence (CLAAD) enables health professionals, law enforcement, businesses, and government, among other entities, to share resources and work together to reduce prescription drug abuse, addiction, and overdoses. CLAAD's National Prescription Drug Abuse Prevention Strategy has been endorsed by 30 non-profit organizations and may be accessed online at  Follow @claad_coalition on Twitter.

[1] Cicero TJ, Ellis MS, Surratt HL. Effect of abuse-deterrent formulation of OxyContin. New England Journal of Medicine. 2012;367(2):187-189.

Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Gateway Foundation Warns K2 is Bad News: K2 Poses Serious Health Risks
2. Solos Endoscopy Sales Increase by More than 35% for the Month of October
3. Frost & Sullivan: Global Increase in Adoption of Real-Time Location Systems Depends on Technological Innovations
4. Mesa Labs Increases Quarterly Dividend
5. Misonix Reports Strong Revenue Increases for the First Quarter of Fiscal 2013
6. Medbox Announces Increase in Shareholder Base and Record Revenue Generated in Q3
7. Watson Third Quarter 2012 Non-GAAP Diluted EPS Increases 24% to $1.35; Net Revenue Increases 19% to $1.29 Billion
8. Global eClinical Trial Solutions Market to 2018 - Growing Complexity of Clinical Trials and Increased Focus on Accuracy and Efficiency Drive Trial Sponsors to Adopt Novel Technologies: MarketResearchReports.Biz
9. Glenmarks Consolidated Revenue Increases by 18.9% to Rs. 12551.9 Mn for Q2 FY12-13
10. Mylan Reports a 51% Increase in Third Quarter 2012 Adjusted Diluted EPS to $0.83
11. Call for Submissions: ICAP Patent Brokerage Announces Expansion of Life Sciences Practice and Increased Buyer Interest in Related Intellectual Property
Post Your Comments:
(Date:11/25/2015)... LYON , Frankreich, November 25, 2015 ... hat heute bekanntgegeben, dass sie eine Lizenz für das ... Inserm, Poxel, CNRS, UCBL und ENS-Lyon innehaben, an Enyo ... 2009 von FUI AAP8 ins Leben gerufenen und von ... NATHEB-Programms wurde FXR als ein Behandlungsziel für HBV identifiziert, ...
(Date:11/24/2015)... Nov. 24, 2015  Natera, Inc. (Nasdaq: ... genetic testing and the analysis of circulating ... present at the 27 th  Annual Piper ... 2015 at 1:00 p.m. ET.  Matthew Rabinowitz, Ph.D., CEO of ... business activities and financial outlook. ...
(Date:11/24/2015)... , 24. November 2015 Avery ... Pacemaker Systems, ist erfreut, die Berufung von ... bekannt geben zu können. ... --> Foto - ... (Schweden). Von 1984-1986 war er Fellow des ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... November 25, 2015 , ... Dr. John Pierce, Medical Director at the Ageless ... treatment with the Capillus272™ Pro laser therapy cap. FDA cleared for safety and efficacy, ... without the need for surgery, prescription pills, or topical foams. , “Capillus272™ Pro ...
(Date:11/25/2015)... ... November 25, 2015 , ... Lakeview Health, ... country to celebrate their sobriety and show through pictures what a positive difference ... photos this Thanksgiving with the hashtag #FacesOfGratitude on their Facebook, Twitter, and Instagram ...
(Date:11/25/2015)... , ... November 25, 2015 , ... On November 23rd ... Tri Lite’s personal heating products business. Cozy Products explains what this means ... that fit in well with the Cozy Products business model: to sell personal heaters ...
(Date:11/25/2015)... MI (PRWEB) , ... November 25, 2015 , ... In ... Presence Resurrection Medical Center (RMC) in Chicago, IL, UV Angel is evaluating the efficacy ... medical and surgical intensive care units (totaling 30 beds) from May 2014 through October ...
(Date:11/25/2015)... PA (PRWEB) , ... November 25, 2015 , ... ... treat my cancer, I found that regular bras were incredibly uncomfortable," said an ... developed this specialized bra." , She developed the patent-pending RECOVERY BRA for added ...
Breaking Medicine News(10 mins):